Mina M. Fam, MD, discusses some of the common misconceptions that patients have when seeking testosterone replacement therapy.

Treatment of non-metastatic hormone-sensitive prostate cancer (nmHSPC) with enzalutamide (Xtandi) in combination with leuprolide acetate was associated with significantly improved overall survival (OS ...

Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.

A recent study in JAMA Network Open found that although trimodal therapy (TMT) improved quality of life for patients with muscle-invasive bladder cancer, it was not as cost-effective as radical ...

Anne K. Schuckman, MD, discusses some of the current challenges in delivering optimal care for patients with non–muscle invasive bladder cancer.

Patient enrollment has been completed for the phase 3 UTOPIA trial (NCT06331299) evaluating UGN-103 (mitomycin) for intravesical solution for the treatment of recurrent low-grade intermediate risk non ...

Zelenectide pevedotin plus pembrolizumab demonstrated a 65% objective response rate in cisplatin-ineligible urothelial carcinoma patients. The combination treatment was generally tolerable, with ...

The FDA granted 510(k) clearance to the Glean Urodynamics System for lower urinary tract dysfunction, enabling wireless, catheter-free monitoring. Darolutamide received FDA approval for metastatic ...

Leflutrozole, an aromatase inhibitor, is being tested in a phase 2 trial for male infertility due to low testosterone levels. The trial will enroll 200 patients, assessing leflutrozole's impact on ...